The recent TGA approval of dupilumab, a biologic therapy aimed at targeting specific immune markers, provides new hope in the treatment of adults with moderate-to-severe atopic dermatitis.
Atopic dermatitis (AD) can be burdensome to the individual and the healthcare system.1 Although 30% of the population are susceptible to AD, of this cohort less than 1% have severe AD. However, the condition is chronic and relapsing and can be debilitating.2 In various forms of severity (i.e. mild, moderate or severe), AD can greatly affect daily function and activities, carrying with it the burden of symptoms such as itch and pain (especially if superimposed infection occurs), which subsequently adversely affect quality of life, with negative psychological impact.3 There is a wide spectrum of clinical presentations and combinations of symptoms in AD. Figure 1, Figure 2 and Figure 3 illustrate severe AD. GPs are often at the forefront of managing AD in the community, with dermatology expertise required for severe and refractory disease.